A presentation made at the 17th International Prostate Cancer Update Conference in Vail, Colorado, has shown noscapine to be effective against prostate cancer.
Noscapine, a non-addictive derivative of opium, has been used worldwide since the 1950's as an anti-cough medication. Noscapine was originally proposed as an anti-cancer agent in the early 1960's. However major studies of its broad anti-cancer effects were only done in recent years.
The study in prostate cancer is the result of ongoing collaboration between the Prostate Cancer Research and Educational Foundation (PC-REF) and MedInsight Research Institute.
Dr. Israel Barken, Founder and Medical Director of the Prostate Cancer Research and Educational Foundation (PC-REF) in San Diego, California, has used noscapine for treating prostate cancer for over a decade. Encouraged by successful results, Dr. Barken's foundation funded a laboratory study to confirm noscapine's effectiveness and mode of action in treating prostate cancer.
"In our study noscapine administered orally to animals had a tumor inhibition rate of 60%, and reduced metastasis by just over 65%. Incredibly, this was achieved with no toxicity thus demonstrating noscapine's potential not only as an effective anti-cancer agent, but a very safe one too," says Dr. Barken.